Tirzepatide, after the hype.
The uncomfortable parts of the GLP-1 boom that rarely make it into glossy before-and-afters: tolerance, muscle retention, cost, access, and what happens when treatment stops.
Tirzepatide deserves the attention. In large randomized trials, the weight-loss signal is materially stronger than first-generation GLP-1 monotherapy, and the metabolic secondary endpoints are difficult to dismiss.
But the consumer internet has flattened a clinical intervention into a lifestyle aesthetic. The actual story is less glamorous: dosing tolerance, lean-mass preservation, cost, access, discontinuation rebound, and the need for long-term monitoring.
What held up
The efficacy data is consistent enough to grade highly. The strongest case is not a single transformation photo; it is a pattern across randomized studies, improved glycemic markers, and durability while treatment continues.
What still needs caution
GI burden remains common, muscle retention needs active management, and stopping therapy is not a neutral event for many patients. Talk to a clinician who understands the tradeoffs before treating this as a shortcut.
Medical note
This review is for education only and is not medical advice. Treatment decisions should be made with a licensed clinician who knows your history, medications, labs, and goals.